Stem Cell Plate Stock Market Capitalization Ranking (List)
Leading stem cell stocks refer to the stocks of listed companies that have a leading position and advantages in the field of stem cell research and application. With the rapid development of the biomedical field, stem cell technology is considered to have great potential and broad application prospects. The following is a ranking of the market capitalization of the stocks in the stem cell sector.
Stem cell plate stock market capitalization ranking
1, Fosun Pharmaceuticals: 93.545 billion yuan
By the close of business at 15:00, Fosun Pharmaceuticals reported 35.040 yuan, a drop of 2.83%, with a total market value of 93.545 billion yuan.
2, Zhaoyan new drug: 31.691 billion yuan
November 25, Zhaoyan new drug opening offer 60.3 yuan, closed at 59.160 yuan, down 2.42%. The highest price of the day was 60.3 yuan, the lowest reached 58.66 yuan, with a volume of 4,229,100 lots and a total market capitalization of 31.691 billion yuan.
3, AVIC property and finance: 28.523 billion yuan
November 25 news, AVIC property and finance opened at 3.18 yuan, closed at 3.230 yuan, up 1.57%. The day's highest price of 3.24 yuan, the lowest reached 3.17 yuan, with a total market capitalization of 28.523 billion.
4, international medicine: 25.46 billion yuan
November 25 news, international medicine opened at 11.41 yuan, closed at 11.190 yuan, down 2.86%. The day's high price of 11.44 yuan, the lowest reached 10.99 yuan, the total market capitalization of 25.46 billion yuan.
5, Tianshili: 17.561 billion yuan
November 25 closing short, Tianshili shares closed down 1.6%, quoted at 11.710 yuan, the market value of 17.561 billion.
6, Dongcheng Pharmaceuticals: 13.828 billion yuan
November 25 closing news, Dongcheng Pharmaceuticals opened at a quote of 17.06 yuan, closed at 16.770 yuan. the share price fell 7.04% in 5 days, the total market value of 13.828 billion yuan.
What are the leading stem cell stocks
Shengjitang: leading stem cell stocks
November 22 opening news, Sanjitang stock price rose 8.9% in 3 days, the latest at 3.260 yuan, turnover of 190 million yuan.
In order to support the normal advancement of the stem cell new drug research and development project of Zhongguang Bio, and to provide convenient conditions for the next development of Zhongguang Bio, the company intends to increase its capital of Zhongguang Bio by 66 million yuan in cash.
Guanhao Bio: leading stem cell stock
November 22 news, Guanhao Bio as of the close of trading at 15:00 hours, the stock reported 11.490 yuan, down 3.2%, the stock price fell 3.31% in 3 days, the total market value of 3.047 billion yuan.
The company began in 2013 to build cell and stem cell R & D application platform, has the only domestic GMP site certification of the two cell production line, the production line follows the GMP workshop "standardization, standardization", in the safety and effectiveness of cell storage follow the highest international standards for the future of the country. The two cell production lines follow the "standardization and normalization" of GMP workshops, and follow the highest international standards in terms of safety and effectiveness of cell storage, providing a model standard for the establishment of the GMP certification system for cell production lines in the future.
Rongjie Health: leading stem cell stocks
November 22 opening news, Rongjie Health latest report 3.750 yuan, volume of 31,855,400 lots, the total market value of 3.015 billion yuan.
The company, as one of the leading enterprises in the domestic health industry, is committed to providing people with family health supplies service enterprises, has initially formed a people's "healthy life" service platform, from the basic health checkups, to the "treatment of the disease" auxiliary Supplies far infrared physical therapy room, massage chairs, massage equipment, fitness equipment and other categories of health appliances, and then to high-end Chinese medicine diagnosis and treatment, stem cell biotechnology and other health management services, the company has covered.
Stem cell concept stock other:
International medicine: the last 5 days the stock price rose 4.78%.
Four Rings Bio: shares down 1.44% in the last 5 days and -6.34% in 2022.
Suzhou Changchai A: Looking back at the last 5 trading days, Suzhou Changchai A has declined on 3 days. It lost 2.79% overall during the period, with a high of $5.38 and a low of $4.93, on a total volume of 61,021,200 lots.
North Pharmaceuticals: Reviewing the last 5 trading days, North Pharmaceuticals has 4 days up. It rose 4.89% overall during the period, with a high of $10.39 and a low of $8.59, on a total volume of 326 million lots.
2023 Stem Cell Leading Stocks List
1, Guanhao Biological: Leading Stocks
The second quarter of 2022 Guanhao Biological Company's main business for the biological type of dura mater (spinal) membrane patch, neurosurgical equipment and accessories, Benvimod, etc., revenues of 47.6835 million yuan, 41.5541 million yuan, 28,531,400 yuan, accounting for 23.5%%, 20.48%%, 14.06%%.
Guanhao Bio released its Q3 2022 financial results, realizing operating income of 91.107 million yuan, up -16.87% year-on-year, and net profit of 12.412 million yuan, up -36.58% year-on-year; and earnings per share of 0.05 yuan.
2, Shengjitang: leading stocks
Shengjitang company's main business in the second quarter of 2022 for urea, methanol, compound fertilizer, etc., revenues of 778 million yuan, 378 million yuan, 129 million yuan, accounting for 56.43%%, 27.4%%, 9.39%%.
The financial report shows that in the third quarter of 2022, the company's operating income of 550 million yuan; net profit attributable to listed shareholders of -127 million yuan; fully diluted return on net assets of -4.22%; gross profit margin of 1.45%, earnings per share -0.08 yuan.
3, rongjie health: leading stocks
2022 second quarter rongjie health company's main business for the far infrared physical therapy room, fitness equipment, air purifiers, etc., revenues of 139 million yuan, 26,823,600 yuan, 16,237,500 yuan, accounting for 59.07%%, 11.36%%%, 6.88%%.
Rongjie Health released its Q3 2022 financial results, realizing operating revenue of 94.5235 million yuan, up -4.88% year-on-year, and net income of 3.7131 million yuan, -82.7% year-on-year.
4, Zhongyuan Xiehe: leading stocks
In the second quarter of 2022 Zhongyuan Xiehe company's main business for the test reagents, cellular assay preparation and storage, scientific research reagents, etc., revenues of 403 million yuan, 211 million yuan, 103 million yuan, accounting for 52.74%%, 27.6%%, 13.49%%.
Zhongyuan Concordia released its Q3 2022 financial results, realizing operating income of 407 million yuan, up 4.01% year-on-year, and net profit of 49.7183 million yuan, up -37.94% year-on-year; earnings per share was 0.1 yuan.
What are the stem cell concept stocks listed companies
1, Fosun Pharmaceuticals (600196): the company's main business for the pharmaceutical manufacturing and R & D. April 21 opening news, Fosun Pharmaceuticals this year, down -9.51%, the latest at 32.480 yuan, turnover 497 million yuan.
2, AVIC Industrial Finance (600705): the company's main business is diversified financial services. April 21 news, AVIC Industrial Finance 5 days the share price fell 6.05%, the stock's latest report 3.800 yuan down 2.31%, turnover of 302 million yuan, turnover rate of 0.89%.
3, Zhaoyan new drug (603127): the company is engaged in drug preclinical research services and laboratory animal breeding and sales. April 21 news, Zhaoyan new drug the latest offer of 53.570 yuan, 3 days the share price fell 5.13%; this year's gain fell -8.34%, price-earnings ratio of 26.65.
4, international medicine (000516): The company is engaged in medical services. open news on April 21, international medicine shares fell 9.58% in 3 days, the latest at 10.650 yuan, turnover of 227 million yuan.
5, tianshili (600535): the company is engaged in modern Chinese medicine, chemical drugs. As of 15:00 close, Tianshili reported 15.410 yuan, down 0.45%, with a total market capitalization of 23.11 billion yuan.
6, Dongcheng Pharmaceutical (002675): the company's business has APIs, nuclear medicine, general preparations (chemical and traditional Chinese medicine). April 21 news, Dongcheng Pharmaceuticals as of 15:00, the stock at 15.560 yuan, up 0.26%, the share price fell by 5.27% in 3 days, the total market value of 12.831 billion yuan.
7, Nanjing Xinbai (600682): the company is mainly engaged in commercial retailing. April 21 news, Nanjing Xinbai this year, down -12.5%, the latest at 8.160 yuan, down 1.21%, turnover 68.732 million yuan.
8, is the sea biological (300653): the company is mainly engaged in biological regenerative materials research and development, production and sales. April 21 opening news, is the sea of biological 5-day share price fell 5.39% this year, up 7.04%, the latest reported 46.590 yuan, turnover 75.4631 million yuan.